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ABSTRACT
Introduction Compression is the mainstay of treatment 
for venous leg ulcers (VLUs) and there are few effective 
adjuvant treatments. There is only observational evidence 
supporting the use of hypochlorous acid (HOCl) as a topical 
wound solution on VLU and some limited randomised 
evidence for the effect of a prescribed regimen of exercise.
Methods and analysis The Factorial4VLU trial is a 
pragmatic, blinded, factorial randomised controlled 
trial, with 380 participants receiving either a prescribed 
exercise regimen compared with usual care and either 
active HOCl wound solution or placebo wound solution at 
each dressing change for up to 24 weeks. All participants 
will receive compression therapy. The primary outcome is 
the proportion of participants with healed VLU at 12 weeks 
after randomisation as adjudicated by blinded review of 
ulcer photographs. Secondary outcomes are proportion 
healed at 24 weeks, time to healing, estimated change 
in ulcer area, change in 2- Minute Walk Test, change in 
health- related quality of life, incidence of infection and 
incidence of all- cause adverse events. If either of the 
interventions shows a statistically significant positive 
difference on healing outcomes, cost- effectiveness will be 
modelled using a health service perspective.
Ethics and dissemination The Factorial4VLU trial 
received ethical approval from the Northern B Health and 
Disability Ethics Committee. We plan to publish the results 
within 1 year of trial completion and will include the results 
on the trial registration page.
Trial registration numbers Australia and New Zealand 
Clinical Trials Register (http://www. anzctr. org. au) 
(ACTRN12620000116921); Universal Trial Number (WHO) 
(U1111-1236-2997).
INTRODUCTION
Effective treatment for venous leg ulcer-
ation (VLU) involves correcting the under-
lying venous hypertension associated with 
chronic venous insufficiency with a form of 
compression therapy. However, about half 
of treated patients remain unhealed after 
12 weeks.1 2 Early endovenous ablation of 
superficial venous reflux increases VLU 
healing,3 but the procedure is not funded 
in New Zealand and may not be readily 
available or accessible in other jurisdictions. 
Pentoxifylline is available in New Zealand,4 
but its use is limited, despite guideline 
recommendations.5 Thus, other adjuvant 
treatments are needed to promote ulcer 
healing. In this study, we examine the role 
of exercise and topical hypochlorous acid 
(HOCl) as adjuvant treatments.
Exercise and VLU healing
Calf muscle contraction promotes venous 
return but dysfunction in the calf muscle 
pump along with valve impairment or 
damage in the venous bed leads to venous 
hypertension allowing fluid and large mole-
cules to escape into surrounding tissue, 
Strengths and limitations of this study
 ► This trial will evaluate the effectiveness of two inter-
ventions within one trial.
 ► This trial uses a pragmatic design to maximise ex-
ternal validity of the findings.
 ► While the hypochlorous acid intervention is fully 
blinded, the exercise intervention is single blinded 
with blinded adjudication of the complete healing 
outcomes via ulcer photographs. Being open label 
for all other outcomes in the exercise arm may in-
troduce bias into some outcome assessments, for 
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causing oedema and trophic skin changes. The most 
severe effect of these changes is VLU. VLU is associ-
ated with poorer calf muscle strength and reduced 
calf muscle endurance,6 7 lower calf muscle pump ejec-
tion fractions and greater residual volume fractions.8 
Patients with VLU also tend to walk less than those 
without VLU.9
A systematic review of adjuvant exercise interventions 
for treating VLU found five trials (n=190) of different 
exercise regimens that could be included in a meta- 
analysis.10 The overall effect was in favour of exercise, 
with 14 extra cases healed per 100 patients at 12 weeks 
(risk difference 14%, 95% CI 1% to 27%). Subgroup 
analysis by type of exercise regimen showed the addi-
tion of 30- minute walking three times per week, or a 
similar activity, to a daily regimen of progressive resis-
tance exercise appeared to increase VLU healing at 12 
weeks by an extra 27 cases healed per 100 patients (two 
trials, n=102, risk difference 27%, 95% CI 9% to 45%).
The two trials in this subgroup were small and differed 
in mode of delivery. One trial (n=63) was home based, 
while the second trial was gym based and there were 
differences in the exercise regimens.11–13 However, the 
use of gyms is not a scalable intervention in most coun-
tries, whereas home- based exercise regimens that do not 
require extra equipment are an intervention that could 
be widely deployed.
The effects of HOCl on wound healing
Static progress to wound healing is associated with 
chronic infection and may be caused by biofilms.14 
However, identifying biofilm in wounds is difficult as 
wounds with devitalised tissue do not invariably support 
a biofilm, whereas wounds that appear healthy can 
support biofilm.15 Bioburden (the quantity of bacteria 
present in a wound) is also associated with wound dura-
tion, with longer duration wounds having a greater 
presence of bacterial species that are known to inhibit 
healing.16
HOCl is water and sodium chloride electrolysed to 
create reactive oxygen and chlorine in a pH neutral 
solution that has antimicrobial activity.17 HOCl can 
disrupt and prevent biofilm and is bactericidal in low 
concentrations against common species that are asso-
ciated with delayed healing, for example, Pseudomonas 
spp.17 Two trials (n=100) of HOCl in diabetic foot ulcers 
(DFUs) have used healing as an outcome, but both trials 
compared HOCl with povidone- iodine, which is not a suit-
able comparison group to extrapolate to VLU.18 19 HOCl 
use has been reported in four case series of VLU, with 
minimal adverse effects and suggested improvements in 
healing,16 17 20 21 but there are no randomised trials of 
HOCl in VLU.
Thus, there is a need for definitive trials of both exer-
cise and HOCl for treating VLU. The aim of this factorial 
trial is to evaluate the effectiveness of each intervention 
on VLU healing as an adjunct to compression therapy.
METHODS AND ANALYSIS
Trial design
The Factorial4VLU trial is a pragmatic, blinded, factorial 
randomised controlled trial with participants receiving 
either a prescribed exercise regimen compared with usual 
care and either HOCl wound solution or placebo wound 
solution at each dressing change (figure 1) for up to 24 
weeks. Block randomisation is being used, stratified by 
study centre and prognostic index (ulcer size and dura-
tion)22 to ensure a balance of participants with severity of 
ulceration within study centres and to isolate any centre 
effect. Participants in both arms will receive compression 
therapy (specific compression system guided by patient 
and/or clinical preference), which is standard care deliv-
ered by district nursing services at the study centres.
Case definition
A patient will be considered to have a VLU where other 
causative aetiologies have been ruled out, the ulcer appears 
clinically venous (presentation may include any or all of 
the following: moist, shallow, irregular shape; haemosid-
erin pigmentation; venous eczema; ankle oedema; ankle 
flare; lipodermatosclerosis), and the patient has an Ankle 
Brachial Index of greater than or equal to 0.8 obtained 
within the last 3 months to rule out significant arterial 
insufficiency. There will be no minimum or maximum 
ulcer area for inclusion.
An incident VLU will be either (a) any new lesion in the 
skin on the leg (below the knee) that has been present for 
4 or more weeks and meets the case definition for VLU, 
or (b) where a patient with a history of VLU re- presents 
to the service earlier than 4 weeks since onset of the lesion 
where the new ulcer is diagnosed as a VLU. Patients 
already in compression treatment for VLU will be consid-
ered to have prevalent VLU. Patients with incident and 
prevalent VLU will be eligible for the trial.
Inclusion criteria
Patients with leg ulcers will be eligible for inclusion if they 
are aged 18 years or older and able to provide written 
informed consent, determined to have a VLU, able to 
tolerate compression therapy and are judged as being 
able to safely mobilise (with or without walking aids) by 
the research nurse.
Exclusion criteria
Patients will be excluded from participation if they have 
a hypersensitivity to HOCl or sodium hypochlorite, have 
a fixed ankle joint (ie, surgically fixated, not a joint with 
restricted range of motion), a VLU with exposed bone 
or tendon, a history of rheumatoid arthritis or vasculitis, 
uncontrolled diabetes (defined as glycosylated haemo-
globin >100), severe liver failure (indicated by jaundice), 
severe heart failure (defined as short of breath while 
seated), or renal failure (estimated glomerular filtration 
rate <30), severe peripheral arterial disease (defined 
by inability to walk even short distances without pain), 
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leg ulcer, or any other threat to safe participation. Patients 
with wound infection requiring treatment with antibiotics 
or a medicated dressing at registration will be deferred 
from consideration until the infection resolves.
Consent
All participants will receive a participant information 
sheet (PIS) that includes the informed consent form 
(ICF). The research nurses will discuss the PIS/ICF with 
potential participants as well as any other persons the 
participant wishes to include, for example, caregivers or 
family members. Participants must give written informed 
consent if they wish to participate. Participation is volun-
tary and participants will be free to withdraw at any time 
without this decision influencing their usual treatment.
Recruitment
Patients with VLU will be recruited from the community- 
based district nursing services at study centres, starting 1 
March 2020 through to 30 October 2021, with follow- up 
concluded by 1 May 2022. The centres are based in 
the Auckland, Counties Manukau, Capital and Coast, 
and Southern District Health Boards district nursing 
services and the Nurse Maude Association community 
nursing services in four cities in New Zealand (Auckland, 
Wellington, Christchurch and Dunedin). A 0.5 full time 
equivalent research nurse has been seconded to the trial 
from each study centre. All but one research nurse have 
been involved in our previous trials and they all received 
2- day induction training in the trial procedures, which 
has been followed up by six weekly Zoom meetings to 
discuss and resolve any implementation issues.
Potentially eligible patients will be identified from 
screening by the research nurses or by notification from 
community nurses (figure 2). The research nurses will 
phone and visit these patients to screen for eligibility 
and obtain informed consent to participate. The location 
for these visits may be a clinic, the patient’s home, work-
place, or other venue convenient to, and nominated by, 
the participants. Eligible patients with incident VLU must 
be treated for 1 week with compression therapy before 
randomisation to ensure they are tolerant of compres-
sion. Patients with prevalent VLU in compression may be 
randomised immediately after registration and baseline 
assessments.
Randomisation and allocation concealment
Participants will be randomised in a 1:1 ratio to one of the 
four trial cells using stratified block randomisation with 
block sizes of 4. Randomisation will be stratified by trial 
centre and prognostic index (one stratum being VLU 
<5 cm2 and <6- month duration with the second stratum 
being either VLU area >5 cm2 or VLU duration >6 months, 
or both VLU area >5 cm2 and VLU duration >6 months).22 
The randomisation sequence will be prepared by the trial 
statistician and loaded into Research Electronic Data 
Capture (REDCap) databases to be accessed one partici-
pant at a time by the research nurse via a computer tablet 
(Samsung S6 LTE) at the point of randomisation.
Blinding
The HOCl wound solution arm of the trial will be 
placebo- controlled (purified water with added preser-
vative to provide the same shelf life once opened as the 
Figure 1 Factorial4VLU trial design showing each allocation by cell. P
rotected by copyright.
 on F
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Figure 2 Detailed trial schematic showing participant contacts and measures. HRQoL, health- related quality of life; ICF, 
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HOCl solution) with the active and placebo solutions 
contained in matching bottles. The investigators, partici-
pants, research nurses and district nurses will be blinded 
to the intervention in the HOCl arm of the trial.
It is not possible to blind participants, research nurses 
and community nurses to the participant’s assignment to 
exercise. However, outcome assessment for the primary 
endpoint and two secondary endpoints (proportion 
healed at 24 weeks and time- to- complete healing) will be 
blinded by using assessors (AJ, JW) unaware of treatment 
allocation to adjudicate the healing status of the ulcer 
from the endpoint photographs. Where a status cannot 
be determined from the photograph, the ulcer will be 
considered unhealed. Where the adjudicators disagree, 
they will meet to arrive at a consensus decision on the 
ulcer status. These processes were successfully used in a 
previous trial, where the agreement between the adjudi-
cators was 91% (kappa 0.81), and agreement between the 
research nurses and adjudicators was 96% (kappa 0.93).23
Photographs of the leg and reference ulcer will be taken 
at baseline and endpoint by the research nurses using a 
Panasonic Lumix TZ80 with autoflash and macro- settings 
and loaded onto a secure web- based server (OwnCloud). 
The baseline photographs will be available to the adju-
dicators to ensure the same ulcer (or ulcer site) is being 
reviewed for the 12- week and 24- week endpoint adjudi-
cations. The photographs will be assessed by the study 
project manager and the principal investigator shortly 
after each visit to ensure image quality. If the image quality 
is poor, the research nurse will return to the participant to 
rephotograph the leg and reference ulcer (or ulcer site).
On study completion, the Trial Steering Committee 
(TSC) will interpret study results blinded to treatment 
allocation and the code broken only after TSC agrees to 
an interpretation.
Sample size calculation
We estimate 380 participants will be required. A sample 
size of 344 will be sufficient to show a 17% absolute differ-
ence in proportion completely healed at 90% power with 
an alpha of 0.05 at 12 weeks. This difference is smaller 
than the 27% difference in healing found in the system-
atic review of exercise trials or the 55% difference in 
healing found in the HOCl trial in DFUs.10 18 Despite our 
previous trials having very high follow- up rates (98%–
100%) on the primary outcome,1 2 24 we have allowed for 
10% loss to follow- up, and thus 190 in each group will be 
required if our assumptions are correct.
While a minimum of 24- week follow- up is recom-
mended in VLU trials and a time- to- event outcome is 
preferable for primary outcome,25 we had no informa-
tion on the likely effects of either exercise or HOCl on 
VLU healing at 24 weeks on which to base a sample size 
calculation. We did have sufficient information to use for 
number healed at 12 weeks and hence our choice of that 
outcome as primary outcome on which to base a sample 
size calculation.
Baseline data collection
Demographic data collection will include age, sex, self- 
identified ethnicity, education, employment, height, 
weight, smoking history, ulcer history (duration, size, 
number of episodes, type of compression system, Clin-
ical Venous Severity Score and pain), clinical history 
(diabetes, history of deep vein thrombosis, joint replace-
ment, leg fractures, treatments for varicosities), estimated 
walking time per week and current medications (table 1). 
We will also collect health- related quality of life (HRQoL) 
assessments and distance walked using a 2- Minute Walk 
Test (2MWT). All data will be entered into REDCap by 
the research nurses.
Primary outcome
The primary outcome is the proportion of patients to 
have a healed reference ulcer (defined at baseline assess-
ment as the largest VLU where there is more than one 
VLU) at 12 weeks as adjudicated by the blinded review of 
ulcer photographs. Healing will be defined as complete 
epithelialisation of the reference ulcer with absence of 
scab. If a light scab is present, the research nurses will 
gently remove it in order to determine whether there is 
complete epithelialisation under the scab.
Secondary outcomes
Secondary outcomes are limited to time to healing, 
proportion of patients with a healed VLU at 24 weeks, 
change in ulcer pain to 12 weeks, estimated change in 
ulcer area from baseline to 24 weeks, change in 2MWT 
at 24 weeks, change in HRQoL at 24 weeks, exercise 
adherence to 24 weeks, and incidence of systemic VLU 
infection and incidence of adverse events (table 1). 
Agreement between the research nurse assessors and the 
blinded adjudicators on the 12- week and 24- week healing 
outcomes will be reported. While high levels of agree-
ment have been reported in trials reporting both blinded 
and open- label outcome assessor, unblinded assessors do 
overestimate treatment effects.26
Change in ulcer area will be estimated using a pragmatic 
approach to ulcer measurement. We will use maximum 
ulcer width and length as inputs into calculating the area 
of an ellipse. The area of an ellipse is closely correlated to 
actual ulcer area (r=0.95),27 which we have verified from 
analysis of our data (r=0.92) from a previous trial.1
Change in HRQoL will be assessed using two generic 
instruments, the Short Form-12 and EuroQoL 5 
Dimension 5 Level (EQ5D- 5L),28 29 and one disease- 
specific instrument, the Charing Cross Venous Ulcer 
Questionnaire.30
For change in ulcer pain, all participants will self- record 
ulcer pain once each week for 12 weeks using a 0–10 pain 
score in a participant diary, prompted by an automated 
email reminder or a text from the research nurse (where 
the participant does not have an email address).
The 2MWT is an objective measure of function. It will 
be measured at baseline and at 12 and 24 weeks. Between- 
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a meaningful clinical difference.31 Change in 2MWT will 
obtained from a timed test of all participants at baseline, 
12 and 24 weeks. Each participant will be asked to walk 
around an indoor course of two cones laid out 3 m apart 
within the visit setting, that is, in a hallway within the home 
or clinic. The number of 3- metre lengths completed 
within 2 min will be counted and the completed distance 
estimated from the number of lengths. Where a partici-
pant finishes the 2 min between the cones, the distance 
will be measured from centre of the last cone passed to 
the heel of the participant.
Exercise adherence for the participants in the exercise 
arm will be measured until 24 weeks. Participants will be 
asked to log the completed number of heel raises and 
walking each day in an exercise diary provided at rando-
misation until the 24- week endpoint. Participants will be 
sent an automated email reminder each week (generated 
in REDCap), or if they do not have an email address, they 
will receive a weekly text or call from the research nurse.
Incidence of systemic VLU infection will be measured 
three ways: (1) proportion of patients that have suffered 
infections up to 24 weeks; (2) incidence of VLU infec-
tions up to 24 weeks and (3) time to first episode of infec-
tion at 24 weeks. We will use a simple empirical definition 
of infection, namely presence of signs and symptoms of 
infection in the ulcer combined with treatment with anti-
biotics. Episodes of infection will be treated as indepen-
dent if more than 21 days passes between prescriptions. 
We will obtain the information about antibiotic use as 
part of concomitant medication data collected at 12 and 
24 weeks, and from the participant’s clinical record and 
electronic community- dispensing portals.











Timing Week −1 Week 0 Weeks 1–24 Week 12 Week 24
Case record form A B, M, Q   C, M, X C, H, M, Q, X
General data
  Eligibility criteria X X       
  Age and sex X         
  Ethnicity X         
  Informed consent X         
  Clinical history X         
  Record or obtain ABI X         
Clinical information
  Concomitant medications   X   X X
  Compression system   X   X   
  Ulcer measurement
(max W×L)
X X   X   
  Photograph ulcer   X   X X
  Ulcer healing       X X
Other data collection
  Ulcer- related pain to 12 
weeks
  X X X   
  Exercise adherence to 24 
weeks
    X   X
  Quality of life measures   X     X
  Ulcer- related infection       X X
  2- Minute Walk Test   X   X X
  Adverse events     X X X
  Health resource use         X
  End of trial participant survey         X
Treatment allocation
  Wound solution   X       
  Exercise programme   X       
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All- cause adverse events, including serious adverse 
events (SAEs), will be reported to the research nurse 
by either participants or district nurses throughout 
the follow- up period. Reporting will also be prompted 
during research contacts at weeks 12 and 24. An adverse 
event will be defined as any untoward medical event 
irrespective of whether it is thought to be related to the 
treatment or not. Adverse events reports will be reviewed 
by one of the medically qualified co- investigators blinded 
to participant allocation, with the relationship to treat-
ment coded using the WHO Uppsala Monitoring Centre 
system for causality assessment.32 Adverse events will 
be coded using the Medical Dictionary for Regulatory 
Activities and study- specific leg ulcer codes. SAEs will 
include hospitalisation or prolongation of hospitalisa-
tion, life- threatening condition, significant disability or 
impairment, death, birth defect or any other important 
medical event. SAEs will be notified to the study project 
manager as soon as they are detected and will be moni-
tored to resolution by the coordinating centre. Although 
not anticipated, any sudden unexpected serious adverse 
reactions (SUSARs) will be documented and notified 
to TSC, the Data Safety Monitoring Board (DSMB), 
the ethics committee, and the manufacturer, if appro-
priate, as soon as the coordinating centre is alerted to 
the SUSAR.
Cost-effectiveness modelling
Should either of the interventions be effective, we will 
conduct cost- effectiveness modelling to assess the costs 
and consequences of using exercise or HOCl as an adju-
vant to compression therapy in community- based partici-
pants with VLUs. We will use a health service perspective 
to identify the cost of the interventions. We know from a 
previous study that the major cost drivers will be the use 
of health services.1 These costs include district nursing 
time, dressing materials and compression bandages used 
at each visit, general practitioner and other practitioner 
visits for VLU care, drugs dispensed for VLU treatment 
and secondary care (emergency department visits and 
days hospitalised for VLU treatment). We will be able 
to determine the number of community nursing visits, 
community drug dispensing and hospitalisations from 
electronic records at each study site. We will elicit infor-
mation on compression systems and dressings at the base-
line, 12- week and 24- week visits, as well information about 
other primary care visits during the 12- week and 24- week 
visits. We will use published resources to estimate costs, 
with local costs used if published resources are not avail-
able. We will establish health utilities using the EQ5D to 
produce quality- adjusted life years (QALYs). Costs will be 
annualised (as the follow- up period is for 24 weeks) and 
the final models (base case and alternatives) will report 
on the incremental cost- effectiveness ratio (cost per addi-
tional healed VLU) and cost per QALY. We will use boot-
strapping to estimate levels of uncertainty around the 
point estimates.
Statistical analyses
Data analyses will be specified a priori in a statistical anal-
ysis plan prepared by the trial statistician (and agreed 
by all members of the TSC). Data will be entered into 
REDCap databases hosted at the University of Auckland. 
REDCap is a secure, web- based application designed to 
support data capture for research studies.33 The data will 
be extracted into SAS V.9.4 (SAS Institute) for analysis.
Analysis will be at the margins comparing each inter-
vention (exercise vs no exercise, HOCl vs placebo). There 
will be no analysis for interaction and analyses will use the 
intention- to- treat principle. Binary outcomes will be anal-
ysed using logistic regression. Sensitivity analyses will be 
undertaken to determine the impact of missing data and 
adherence. Continuous outcomes (with 95% CIs) will be 
analysed using multiple linear regression and adjusted 
for baseline value and other covariates if needed. Change 
in ulcer- related pain will be analysed using repeated 
measures model with adjustment for baseline value. Time- 
to- event data will be analysed using Kaplan- Meier plots 
and log rank test. Cox regression will be used with time- 
to- event data adjusted for stratification factors and any 
imbalance in covariates. The assumption of proportion-
ality will be checked using standard graphical techniques. 
Adverse events will be analysed using incidence rate ratios 
with reporting guided by the Consolidated Standards of 
Reporting Trials extension statement on reporting of 
harms and a recent systematic review on adverse event 
reporting in VLU trials.34 35 No interim analyses will be 
undertaken.
Should the treatments prove effective in the primary 
analysis, heterogeneity of effects will be analysed on 
proportion healed using subgroups specified a priori 
in the analysis plan. Likely subgroups will be age, sex, 
ethnicity, ulcer size at baseline, ulcer duration, prognostic 
index and study centre.
Treatment period and follow-up
The allocated treatment will be continued until complete 
healing or end of the trial after 24 weeks’ treatment. The 
research nurses are trained in leg ulcer care and most 
have been involved in previous 4VLU trials. The research 
nurses will deputise for the community nurses on research 
visits. In between research visits, care will be delivered by 
community nurses. All participants will be followed up 
at the scheduled timepoints irrespective of whether they 
continue with the assigned treatment (figure 2). The only 
exception to follow- up will be if the participant requests 
withdrawal of their data from the trial.
Intervention and control treatments
Participants will be allocated to one of four cells in this 
factorial trial (figure 1) and these treatments are all in 
addition to compression therapy.
Cell 1: prescribed regimen of exercise and active HOCl. 
The prescribed regimen of progressive resistance exer-
cise consists of daily lower leg exercises to increase calf 
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seated exercises starting with 10 repetitions per set and 
increasing up to 25 repetitions per set, before progressing 
to standing two- legged exercises and then standing one- 
legged exercises) with the participants' body weight 
providing the resistance element. Participants progress 
to the next stage of exercise when they are comfortable 
with achieving the current step. The exercise regimen 
is supported with a resource book that provides general 
advice about venous ulceration and demonstrates the 
exercises, plus includes a goal setting diary (which will 
be assisted by trained research nurses) and an exercise 
diary to record adherence. The prescribed regimen also 
includes a target of walking for 30 minutes each day, 3 days 
per week. The regimen will be demonstrated one- to- one 
by the research nurses. Participants will perform the 
resistance exercises wherever they are comfortable, for 
example, their own home for the duration of the trial (24 
weeks) or until the ulcer is healed, whichever is earlier.
The HOCl wound solution will be sprayed on the ulcer 
at each dressing change, the wound debrided as required, 
devitalised tissue and debris will be removed, and then the 
wound solution reapplied before the ulcer is redressed. 
Venous ulcers are typically redressed once per week, but 
may be redressed more frequently as indicated. Dressings 
are usually changed by nurses, but may be changed by 
some self- managing patients if they are wearing compres-
sion hosiery or wraps. The wound solution will be used 
for the duration of the trial (24 weeks) or until the ulcer 
is healed, whichever is earlier.
Cell 2: prescribed regimen of exercise and placebo HOCl (puri-
fied water plus preservative). The prescribed regimen of 
progressive resistance exercise and the use of the purified 
water wound solution is as described in arm 1.
Cell 3: usual care and active HOCl wound solution. The 
usual care regimen is supported by a participant resource 
book that provides general advice about venous ulcer-
ation. The wound solution will be sprayed on the ulcer at 
each dressing change, the wound debrided as required, 
devitalised tissue and debris will be removed, and the the 
wound solution reapplied before the ulcer is redressed. 
The wound solution will be used for the duration of the 
trial (24 weeks) or until the ulcer is healed, whichever is 
earlier.
Cell 4: usual care and placebo HOCl (purified water plus 
preservative). The usual care regimen and the use of the 
purified water wound solution will be as described in arm 
3.
Background treatments
All participants will receive compression therapy as a 
background treatment. The choice of compression 
system will be guided by clinician and/or patient prefer-
ence included in the centre’s formulary, such as Coban, 
Coban Lite, Coban Self- adherent, Comprilan, Lastodur, 
Profore, Profore Lite, Roselastic, Setopress, Surepress, 
compression hosiery and wraps. Any primary and 
secondary dressing may be used with the chosen compres-
sion system.
Throughout the trial, a participant’s general prac-
titioner, nurse practitioner or specialist physician will 
be free to prescribe whatever concomitant treatments 
are necessary for the appropriate management of their 
patients. Concomitant medications, including comple-
mentary and alternative treatments, supplements and 
vitamins, will be recorded at each research visit.
Where a participant develops an infection related 
to the VLU during the course of treatment, the district 
nurses may use a medicated dressing for the treatment 
of the infection for recommended maximum period of 
2 weeks. The medicated dressing will be selected from the 
formulary of medicated dressings available at each study 
centre, including silver, iodine, or honey- impregnated 
dressings as per clinician and/or participant preference. 
The participant will also be referred to a general practi-
tioner or nurse practitioner for a prescription of an anti-
biotic where warranted. Each infection will be considered 
an adverse event, and participants and district nurses will 
be requested to notify the research nurse.
Data safety and monitoring
A DSMB has been established to review safety informa-
tion. The DSMB consists of a senior biostatistician (Chair) 
and two other University of Auckland staff members with 
relevant expertise who are not involved with the trial and 
will meet not less than six monthly. The DSMB will draw 
up their own charter and will be free to review any infor-
mation or study process in addition to reviewing safety 
data. The DSMB will make recommendations to the TSC 
on the continuation of the trial after each meeting or 
after a SUSAR.
The trial will be monitored by the project manager (AW) 
and the following information will be audited: admission 
to the district nursing service to verify the patient detail, 
record of consent, key baseline and outcome variables. 
Monitoring will begin once five participants have been 
randomised at a study centre.
Ethics and dissemination
Ethical approval for the trial was obtained on 6 January 
2020 from the Northern B Health and Disability Ethics 
Committee (Reference 19/NTB/151) by the trial coordi-
nating centre (National Institute for Health Innovation). 
The trial participants are covered by the government- 
funded national no- fault insurance scheme where partic-
ipants suffer harm from their involvement in the trial. 
Locality approvals were obtained from each of the organ-
isations responsible for the participating study centres 
prior to the trial start on 1 March 2020. Changes to the 
protocol are sought as required, incorporated into the 
trial registration as appropriate once notification of 
approval has been received, and communicated to the 
site investigators and research nurses. We will publish the 
peer- reviewed results of this trial in a journal within 1 year 
of completing follow- up. The results will be notified to 
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Trial status
Recruitment to the trial commenced from 1 March 2020 
and five participants were randomised by 19 March 2020. 
On 22 March 2020, due to the COVID-19 pandemic and 
evidence of community transmission in New Zealand, the 
New Zealand government declared ‘level 3’ restrictions 
(gatherings cancelled, public venues closed and defer-
ment of elective healthcare procedures) with planned 
escalation to ‘level 4’ (level 3 restrictions plus suspension 
of all non- essential work, non- essential workers required 
to stay at home, closure of all educational institutions and 
reprioritisation of healthcare services, except for essential 
workers) within 48 hours. In anticipation of these restric-
tions, we decided to suspend recruitment into the Factori-
al4VLU trial on 20 March 2020. Recruitment restarted at 
the study centres on various dates in June 2020. The two 
Auckland centres had a further suspension of recruitment 
for 3 weeks in August–September 2020 due to a commu-
nity outbreak and escalation of restrictions to level 3. 
Negotiations with the study centres have since resulted in 
agreement to continue participant recruitment up to and 
including during level 3 restrictions. Future participant 
recruitment will only be suspended if the government 
announces level 4 restrictions.
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